Journal
Clinical infectious diseases
Publication Date
6-14-2024
Volume
78
Issue
6
First Page
1462
Last Page
1472
Document Type
Open Access Publication
DOI
10.1093/cid/ciad792
Rights and Permissions
Pablo C Okhuysen, Mayur S Ramesh, Thomas Louie, Nino Kiknadze, Julian Torre-Cisneros, Claudia Murta de Oliveira, Christophe Van Steenkiste, Alena Stychneuskaya, Kevin W Garey, Julia Garcia-Diaz, Jianling Li, Esther Duperchy, Betty Y Chang, Juthamas Sukbuntherng, Jose G Montoya, Lori Styles, Fong Clow, Danelle James, Erik R Dubberke, Mark Wilcox, A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response, Clinical Infectious Diseases, Volume 78, Issue 6, 15 June 2024, Pages 1462–1472, https://doi.org/10.1093/cid/ciad792. © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Recommended Citation
Okhuysen, Pablo C; Dubberke, Erik R; and et al., "A randomized, double-blind, phase 3 safety and efficacy study of ridinilazole versus vancomycin for treatment of Clostridioides difficile infection: Clinical outcomes with microbiome and metabolome correlates of response." Clinical infectious diseases. 78, 6. 1462 - 1472. (2024).
https://digitalcommons.wustl.edu/oa_4/3876
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
